Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies

References

• Junyaprasert VB, Morakul B Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci 2015;10(1):13–23.
   Web of Science ®Google Scholar
• Yasuji T, Takeuchi H, Kawashima Y Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv Drug Deliv Rev 2008 Feb 14;60(3):388–398.
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Wada K, Nakatani M, et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharmaceut 2011;420(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ganellin CR, Rotella DP. Analogue-based drug discovery iiI. Germany: John Wiley & Sons; 2012.
   Google Scholar
• Capewell S, Critchley J, Freestone S, et al. Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 1988;332(8609):480–482.
   Google Scholar
• Hetal T, Bindesh P, Sneha T A review on techniques for oral bioavailability enhancement of drugs. Health 2010;4(3):203–223.
   Google Scholar
• Vickers S, Duncan C, Vyas K, et al.In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18(4):476–483.
   PubMed Web of Science ®Google Scholar
• Pongpeerapat A, Wanawongthai C, Tozuka Y, et al. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharmaceut 2008;352(1–2):309–316.
   PubMed Web of Science ®Google Scholar
• Italia J, Yahya M, Singh D, et al. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res 2009;26(6):1324–1331.
   PubMed Web of Science ®Google Scholar
• Sanders S, Haering N, Mosberg H, et al. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986;30(3):331–334.
   PubMed Web of Science ®Google Scholar
• Reed MD, Rodarte A, Blumer JL, et al.The single‐dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001;41(12):1359–1369.
   PubMed Web of Science ®Google Scholar
• Poovi G, Damodharan N Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs. Future J Pharm Sci 2018;4(2):191–205.
   Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Gomez-Orellana I Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005;2(3):419–433.
   PubMedGoogle Scholar
• Singh M, Hemant K, Ram M, et al. Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci 2010;5(2):65.
   PubMedGoogle Scholar
• Whelehan M, Marison IW Microencapsulation using vibrating technology. J Microencapsul 2011 2011 December 01;28(8):669–688.
   PubMed Web of Science ®Google Scholar
• Schreier H, Bouwstra J Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release 1994;30(1):1–15.
   Web of Science ®Google Scholar
• Huang D, Wu D Biodegradable dendrimers for drug delivery. Mater Sci Eng C 2018;90:713–727.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55(3):329–347.
   PubMed Web of Science ®Google Scholar
• Jeong B, Choi Y, Bae Y, et al. New biodegradable polymers for injectable drug delivery systems. J Control Release 1999;62(1–2):109–114.
   PubMed Web of Science ®Google Scholar
• Stojančević M, Bojić G, Salami HA, et al. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol 2013;16(2):55–68.
   PubMedGoogle Scholar
• Sosnik A Alginate particles as platform for drug delivery by the oral route: state-of-the-art. ISRN Pharm 2014;2014:926157.
   PubMedGoogle Scholar
• Liu L, Yao W, Rao Y, et al. pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Deliv 2017;24(1):569–581.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Neuhoff S, Jamei M, et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” model. Curr Drug Metab 2010 Nov;11(9):716–729.
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Silverman JA, Zhang Y, et al. Role of P‐glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87(11):1322–1330.
   PubMed Web of Science ®Google Scholar
• Hamman J, Demana P, Olivier E Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights 2007;2:117739280700200003.
   Google Scholar
• Christians U, Schmitz V, Haschke M Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005;1(4):641–654.
   PubMedGoogle Scholar
• Cummins CL, Jacobsen W, Benet LZ Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300(3):1036–1045.
   PubMed Web of Science ®Google Scholar
• Cummins CL, Jacobsen W, Christians U, et al. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 2004;308(1):143–155.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A, CYP2C9 CC, CYP2D6 CA. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76: 391–396.
   PubMed Web of Science ®Google Scholar
• Chan LM, Lowes S, Hirst BH The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21(1):25–51.
   PubMed Web of Science ®Google Scholar
• De Montellano PRO. Cytochrome P450: structure, mechanism, and biochemistry. US: Springer Science & Business Media; 2005.
   Google Scholar
• Martin J, Fay M Cytochrome P450 drug interactions: are they clinically relevant? Aust Prescr 2001;24(1):10–12.
   Google Scholar
• Nelson DR, Koymans L, Kamataki T, et al.P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6(1):1–42.
   PubMedGoogle Scholar
• Chang G, Kam P The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 1999;54(1):42–50.
   PubMed Web of Science ®Google Scholar
• Krishna DR, Klotz U Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26(2):144–160.
   PubMed Web of Science ®Google Scholar
• Smith DA, Jones BC Speculations on the substrate structure activity relationship (Ssar) of Cytochrome-P450 enzymes. Biochem Pharmacol 1992 Dec 1;44(11):2089–2098.
   PubMed Web of Science ®Google Scholar
• Borkar RM, Bhandi MM, Dubey AP, et al.An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug–drug and drug–herb interaction by LC‐ESI/MS/MS. Biomed Chromatogr 2016;30(10):1556–1572.
   PubMed Web of Science ®Google Scholar
• Ohyama K, Nakajima M, Suzuki M, et al. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49(3):244–253.
   PubMed Web of Science ®Google Scholar
• Mikov M, Danic M, Pavlovic N, et al.The role of drug metabolites in the inhibition of Cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet 2017 December;42(6):881–890.
   PubMed Web of Science ®Google Scholar
• Szekalska M, Pucilowska A, Szymanska E, et al. Alginate: current use and future perspectives in pharmaceutical and biomedical applications. Int J Polym Sci 2016. 2016 1–17
   Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311(1):228–236.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al.Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34(1):191–197.
   PubMed Web of Science ®Google Scholar
• Gan JP, Liu-Kreyche P, Humphreys WG In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin. Cancer Chemoth Pharm 2012 January;69(1):51–56.
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, et al. Evaluation of in vitro Cytochrome P450 inhibition and in vitro fate of structurally diverse N-Oxide metabolites: case studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. Eur J Drug Metab Pharmacokine 2017 August;42(4):677–688.
   PubMed Web of Science ®Google Scholar
• Eng H, Obach RS Use of human plasma samples to identify circulating drug metabolites that inhibit Cytochrome P450 enzymes. Drug Metab Dispos 2016 August;44(8):1217–1228.
   PubMed Web of Science ®Google Scholar
• Sager JE, Lutz JD, Foti RS, et al. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 2014 June;95(6):653–662.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Di Y M, Chan E, et al.Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9(8):738–784.
   PubMed Web of Science ®Google Scholar
• Danielson P The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002;3(6):561–597.
   PubMed Web of Science ®Google Scholar
• Juřica J, Dovrtělová G, Nosková K, et al. Bile acids, nuclear receptors and cytochrome P450. Physiol Res 2016 Dec 21;65(Suppl 4):S427–s40.
   PubMedGoogle Scholar
• Prakash C, Zuniga B, Song CS, et al.Nuclear receptors in drug metabolism, drug response and drug interactions. Nucl Recept Res 2015;2:101178.
   PubMedGoogle Scholar
• Murakami T, Takano M Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008 July;4(7):923–939.
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, et al. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004;1(1):27–42.
   PubMedGoogle Scholar
• Al-Salami H, Butt G, Tucker I, et al. Probiotic pre-treatment reduces Gliclazide permeation (ex vivo) in healthy Rats but increases it in diabetic rats to the level seen in untreated healthy Rats. Arch Drug Inf 2008 July;1(1):35–41.
   PubMedGoogle Scholar
• Al-Salami H, Butt G, Tucker I, et al. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol 2008 March;30(2):107–113.
   PubMedGoogle Scholar
• Al-Salami H, Butt G, Fawcett JP, et al. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet 2008 April-June;33(2):101–106.
   PubMed Web of Science ®Google Scholar
• Mikov M, Boni NS, Al-Salami H, et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet 2007 Jan-Mar;32(1):7–12.
   PubMed Web of Science ®Google Scholar
• Mikov M, Boni NS, Al-Salami H, et al. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. Febs J 2006 Jun;273:210.
   Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109(1–2):137–161.
   PubMed Web of Science ®Google Scholar
• Mikov M, Al-Salami H, Golocorbin-Kon S, et al. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet 2008 Jul-Sep;33(3):137–142.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker IG, et al. The influence of pre-treatment with probiotics on the in vitro ileal permeation of the antidiabetic drug gliclazide, in healthy and diabetic Rats. Drug Metab Rev 2008;40(1):81–82.
   Google Scholar
• Schinkel AH, Jonker JW Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2012;64:138–153.
   PubMed Web of Science ®Google Scholar
• Szakács G, Váradi A, Özvegy-Laczka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov Today 2008;13(9–10):379–393.
   PubMed Web of Science ®Google Scholar
• Hunter J, Hirst BH Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997;25(2–3):129–157.
   Web of Science ®Google Scholar
• Kruijtzer C, Beijnen J, Schellens J Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7(6):516–530.
   PubMed Web of Science ®Google Scholar
• Rodes L, Paul A, Coussa-Charley M, et al.Transit time affects the community stability of Lactobacillus and Bifidobacterium species in an in vitro model of human colonic microbiotia. Artif Cells Blood Substitutes Immobilization Biotechnol 2011 Dec;39(6):351–356.
   PubMed Web of Science ®Google Scholar
• Lalic M, Cvejic J, Popovic J, et al.Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 2009 April-June;34(2):93–99.
   PubMed Web of Science ®Google Scholar
• Al-Salami H, Butt G, Tucker I, et al.Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 2009;34(1):43–50.
   PubMed Web of Science ®Google Scholar
• Gribble FM, Ashcroft FM Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels fromcells and extrapancreatic tissues. Metabolism 2000;49(10):3–6.
   PubMed Web of Science ®Google Scholar
• Al‐Salami H, Butt G, Tucker I, et al. Probiotic pre‐treatment reduces Gliclazide Permeation (ex vivo) in healthy Rats but increases it in diabetic Rats to the level seen in untreated healthy Rats. Arch Drug Inf 2008;1(1):35–41.
   PubMedGoogle Scholar
• Torne SJ, Ansari KA, Vavia PR, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010;17(6):419–425.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Eichelbaum M Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001;1(1):59.
   PubMedGoogle Scholar
• Moore LB, Goodwin B, Jones SA, et al.St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Nat Acad Sci 2000;97(13):7500–7502.
   PubMed Web of Science ®Google Scholar
• Lam JL, Benet LZ Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 2004;32(11):1311–1316.
   PubMed Web of Science ®Google Scholar
• Finch A, Pillans P P-glycoprotein and its role in drug-drug interactions. Aust Prescr 2014;37(4):137–139.
   Google Scholar
• Kawabata M, Yokoyama Y, Sasano T, et al.Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice. J Cardiol 2013;62(2):121–126.
   PubMed Web of Science ®Google Scholar
• Mathavan S, Mikov M, Golocorbin-Kon S, et al. Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. Eur J Pharm Sci 2017 August30;106:1–9.
   Google Scholar
• Pal D, Mitra AK MDR-and CYP3A4-mediated drug–herbal interactions. Life Sci 2006;78(18):2131–2145.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52(5):453–457.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Pan S-Q, et al. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 2004;18(2):262–276.
   PubMed Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Al-Salami H Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellitus 2013;1(2):49–59.
   Google Scholar
• Lalic-Popovic M, Vasovic V, Milijasevic B, et al. Deoxycholic acid as a modifier of the permeation of Gliclazide through the blood brain barrier of a Rat. J Diabetes Res 2013;2013:598603.
   PubMed Web of Science ®Google Scholar
• Tomaro-Duchesneau C, Saha S, Malhotra M, et al.Lactobacillus fermentum NCIMB 5221 has a greater ferulic acid production compared to other ferulic acid esterase producing lactobacilli. Int J Probiotics and Prebiotics 2012;7(1):23–32.
   Google Scholar
• M A-sh M, Golocorbin-Kon G Potentials and limitations of bile acids and probiotics in diabetes mellitus. 2012:365–402.
   Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al.Stability and release kinetics of an advanced Gliclazide-Cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov 2014;9(2):150–157.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther 2014;8:1673–1683.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al.Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther 2014;8:1221–1230.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al.Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther 2014;8:1003–1012.
   PubMed Web of Science ®Google Scholar
• Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res 2014;7:113–120.
   PubMedGoogle Scholar
• Patel MSN, Ahmed MH, Saqib M, et al. Chemical Modification: A unique solutions to Solubility problem. J Drug Deliv Therap 2019;9(2):542–546.
   Google Scholar
• Choi M, Maibach H Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005;18(5):209–219.
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45(1):89–121.
   PubMed Web of Science ®Google Scholar
• Kohli K, Chopra S, Dhar D, et al. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today 2010 November;15(21–22):958–965.
   PubMed Web of Science ®Google Scholar
• Jadon PS, Gajbhiye V, Jadon RS, et al. Enhanced Oral Bioavailability of Griseofulvin via Niosomes. Aaps Pharmscitech 2009 December;10(4):1186–1192.
   PubMed Web of Science ®Google Scholar
• Sinha S, Ali M, Baboota S, et al. Solid Dispersion as an Approach for Bioavailability Enhancement of Poorly Water-Soluble Drug Ritonavir. Aaps Pharmscitech 2010 June;11(2):518–527.
   PubMed Web of Science ®Google Scholar
• Callender SP, Mathews JA, Kobernyk K, et al. Microemulsion utility in pharmaceuticals: implications for multi-drug delivery. Int J Pharmaceut 2017 2017 June 30;526(1):425–442.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of Liposome assisted drug delivery. Front Pharmacol 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Bhardwaj P, Tripathi P, Gupta R, et al. Niosomes: a review on niosomal research in the last decade. J Drug Delivery Sci Technol 2020 2020 April 01;56: 101581.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al.Novel multicompartmental bile acid-based microcapsules for pancreatic beta-cell transplantation. Transplantation 2015;99(11):S151–S2.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al.Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. Aaps Pharmscitech 2015 Feb;16(1):45–52.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al.Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul 2015;32(2):151–156.
   PubMed Web of Science ®Google Scholar
• Gogoi-Tiwari J, Babra Waryah C, Sunagar R, et al.Typing of Staphylococcus aureus isolated from bovine mastitis cases in Australia and India. Aust Vet J 2015August;93(8):278–282.
   PubMedGoogle Scholar
• Fakhoury M, Takechi R, Al-Salami H Drug permeation across the blood-brain barrier: applications of nanotechnology. Br J Med Med Res 2015;6(6):547–556.
   Google Scholar
• Choudhary S, Gupta L, Rani S, et al. Impact of dendrimers on solubility of hydrophobic drug molecules. Front Pharmacol 2017;8:261.
   PubMed Web of Science ®Google Scholar
• Samad A, Alam MI, Saxena K Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des 2009;15(25):2958–2969.
   PubMed Web of Science ®Google Scholar
• Jain NK. Progress in controlled and novel drug delivery systems. New Delhi, India: CBS Publishers & Distributors; 2004.
   Google Scholar
• George S, Vasudevan D Studies on the preparation, characterization, and solubility of 2-HP-β-Cyclodextrin-Meclizine HCl inclusion complexes. J Young Pharm 2012;4(4):220–227.
   PubMedGoogle Scholar
• Becket G, Schep LJ, Tan MY Improvement of the in vitro dissolution of praziquantel by complexation with α-, β-and γ-cyclodextrins. Int J Pharmaceut 1999;179(1):65–71.
   PubMed Web of Science ®Google Scholar
• Devi N, Sarmah M, Khatun B, et al. Encapsulation of active ingredients in polysaccharide-protein complex coacervates. Adv Colloid Interface Sci 2017 January;239:136–145.
   PubMed Web of Science ®Google Scholar
• Senuma Y, Lowe C, Zweifel Y, et al. Alginate hydrogel microspheres and microcapsules prepared by spinning disk atomization. Biotechnol Bioeng 2000 March 5;67(5):616–622.
   PubMed Web of Science ®Google Scholar
• Nagavarma B, Yadav HK, Ayaz A, et al. Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharm Clin Res 2012;5(3):16–23.
   Google Scholar
• Wong CY, Al-Salami H, Dass CR Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J Control Release 2017;264:247–275.
   PubMed Web of Science ®Google Scholar
• Wong CY, Al-Salami H, Dass CR Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin. Int J Pharm 2018 February 15;537(1–2):223–244.
   PubMed Web of Science ®Google Scholar
• Musyanovych A, Landfester K Polymer micro‐and nanocapsules as biological carriers with multifunctional properties. Macromol Biosci 2014;14(4):458–477.
   PubMed Web of Science ®Google Scholar
• Amin ML P-glycoprotein Inhibition for optimal drug delivery. Drug Target Insights 2013;7:27–34.
   PubMedGoogle Scholar
• Wang E-J, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001;18(6):800–806.
   PubMed Web of Science ®Google Scholar
• de Souza Simoes L, Madalena DA, Pinheiro AC, et al. Micro- and nano bio-based delivery systems for food applications: in vitro behavior. Adv Colloid Interface Sci 2017 May;243:23–45.
   PubMed Web of Science ®Google Scholar
• Jain A, Thakur D, Ghoshal G, et al. Characterization of microcapsulated beta-carotene formed by complex coacervation using casein and gum tragacanth. Int J Biol Macromol 2016 June;87:101–113.
   PubMed Web of Science ®Google Scholar
• Xue X, Liang X-J Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer 2012;31(2):100.
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 2005;1(3):193–212.
   PubMed Web of Science ®Google Scholar
• Suri SS, Fenniri H, Singh B Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007;2(1):16.
   PubMedGoogle Scholar
• Lalic-Popovic M, Paunkovic J, Grujic Z, et al.The effect of diabetes and hypertension on the placental permeation of the hydrophilic drug, Ranitidine. Placenta 2016 December;48:144–150.
   PubMed Web of Science ®Google Scholar
• Mooraniana A, Negrulja R, Chen-Tan N, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterisation study. Drug Des Devel Ther. 2014;8:1003.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Takechi R, et al. Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic beta cells. Ther Deliv 2017 October;8(10):833–842.
   PubMed Web of Science ®Google Scholar
• Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5(3):219.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Ahmad A, et al.Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13(4–5):109–118.
   PubMed Web of Science ®Google Scholar
• Sutradhar KB, Amin M. Nanotechnology in cancer drug delivery and selective targeting. International Scholarly Research Notices. 2014;2014.
   Google Scholar
• Russell-Jones G, McTavish K, McEwan J, et al. Increasing the tumoricidal activity of daunomycin-pHPMA conjugates using vitamin B12 as a targeting agent. J Cancer Res Updates 2012;1(2):203–211.
   Google Scholar
• Davoudi Z, Peroutka‐Bigus N, Bellaire B, et al.Intestinal organoids containing poly (lactic‐co‐glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases. J Biomed Mater Res A 2018;106(4):876–886.
   PubMed Web of Science ®Google Scholar
• Ai H, Jones SA, de Villiers MM, et al. Nano-encapsulation of furosemide microcrystals for controlled drug release. J Control Release 2003 2003 January 09;86(1):59–68.
   PubMed Web of Science ®Google Scholar
• Katouzian I, Jafari SM Nano-encapsulation as a promising approach for targeted delivery and controlled release of vitamins. Trends Food SciTechnol 2016 2016 September 01;53: 34–48.
   Web of Science ®Google Scholar
• Shishir MRI, Xie L, Sun C, et al. Advances in micro and nano-encapsulation of bioactive compounds using biopolymer and lipid-based transporters. Trends Food SciTechnol 2018 2018 August 01;78: 34–60.
   Web of Science ®Google Scholar
• Thakkar A, Chenreddy S, Thio A, et al. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine 2016;11:3265–3276.
   PubMed Web of Science ®Google Scholar
• Jia ZH, Dumont MJ, Orsat V Encapsulation of phenolic compounds present in plants using protein matrices. Food Biosci 2016 September 1;15:87–104.
   Web of Science ®Google Scholar
• Orive G, Hernandez RM, Gascon AR, et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol 2004 February; 22(2):87–92.
   PubMed Web of Science ®Google Scholar
• Chávarri M, Marañón I, Ares R, et al. Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions. Int J Food Microbiol 2010;142(1–2):185–189.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R. Al-Salami H Primary bile acid Chenodeoxycholic acid-based microcapsules to examine β-cell survival and the inflammatory response. BioNanoScience 2016 June; 6(2):103–109.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Salami H Alginate-deoxycholic acid interaction and its impact on pancreatic Β-cells and insulin secretion and potential treatment of Type 1 diabetes. J Pharm Innov 2016 June;11(2):156–161.
   Web of Science ®Google Scholar
• Mathavan S, Chen-Tan N, Arfuso F, et al. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif Cells Nanomed Biotechnol 2016 Sep;44(6):1508–1519.
   PubMed Web of Science ®Google Scholar
• Al-Kassas RS, Al-Gohary OM, Al-Faadhel MM Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharmaceut 2007;341(1–2):230–237.
   PubMed Web of Science ®Google Scholar
• Etchepare M, Barin JS, Cichoski AJ, et al.Microencapsulation of probiotics using sodium alginate. Ciência Rural 2015;45(7):1319–1326.
   Web of Science ®Google Scholar
• Schmidt JJ, Rowley J, Kong HJ Hydrogels used for cell‐based drug delivery.J Biomed Mater Res Part A: An Official Journal of the Society for Biomaterials, the Japanese Society for Biomaterials, and the Australian Society for Biomaterials and the Korean Society for Biomaterials 2008;87(4):1113–1122.
   Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al.Advanced bile acid-based multi-compartmental microencapsulated pancreatic β-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol 2016;44(2):588–595.
   PubMed Web of Science ®Google Scholar
• Thanos CG, Bintz BE, Emerich DF Stability of alginate-polyornithine microcapsules is profoundly dependent on the site of transplantation. J Biomed Mater Res A 2007 April;81a(1):1–11.
   Web of Science ®Google Scholar
• DeVos P, DeHaan B, Wolters GHJ, et al. Factors influencing the adequacy of microencapsulation of rat pancreatic islets. Transplantation 1996 October 15;62(7):888–893.
   PubMed Web of Science ®Google Scholar
• Smidsrod O, Glover RM, Whittington SG Relative extension of alginates having different chemical composition. Carbohyd Res 1973;27(1):107–118.
   Web of Science ®Google Scholar
• Jimenez-Escrig A, Sanchez-Muniz FJ Dietary fibre from edible seaweeds: chemical structure, physicochemical properties and effects on cholesterol metabolism. Nutr Res 2000April; 20(4):585–598.
   Web of Science ®Google Scholar
• Ching SH, Bansal N, Bhandari B Alginate gel particles–A review of production techniques and physical properties. Crit Rev Food Sci Nutr 2017;57(6):1133–1152.
   PubMed Web of Science ®Google Scholar
• Sriamornsak P, Thirawong N, Korkerd K Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm 2007 June;66(3):435–450.
   PubMed Web of Science ®Google Scholar
• Yu C-Y, Yin B-C, Zhang W, et al. Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property. Colloids Surf B Biointerfaces 2009;68(2):245–249.
   PubMed Web of Science ®Google Scholar
• Storz H, Müller KJ, Ehrhart F, et al.Physicochemical features of ultra-high viscosity alginates. Carbohyd Res 2009;344(8):985–995.
   PubMed Web of Science ®Google Scholar
• Lee KY, Mooney DJ Alginate: properties and biomedical applications. Prog Polym Sci 2012;37(1):106–126.
   PubMed Web of Science ®Google Scholar
• Lee HY, Chan LW, Dolzhenko AV, et al. Influence of viscosity and uronic acid composition of alginates on the properties of alginate films and microspheres produced by emulsification. J Microencapsul 2006 December; 23(8):912–927.
   PubMed Web of Science ®Google Scholar
• Mathavan S, Chen-Tan N, Arfuso F, et al. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. Drug Deliv 2016;23(8):2869–2880.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al.An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 2015;20(6):702–709.
   PubMed Web of Science ®Google Scholar
• Mamo JC, Lam V, Al-Salami H, et al.Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. Ther Deliv 2018 October; 9(10):703–709.
   PubMed Web of Science ®Google Scholar
• Rao JK, Rao KP Controlled release of FITC-BSA from polymer coated gelatin microspheres. J Bioact Compat Pol 1997 April;12(2):127–139.
   Web of Science ®Google Scholar
• Chan AW, Neufeld RJ Modeling the controllable pH-responsive swelling and pore size of networked alginate based biomaterials. Biomaterials 2009 2009 October 01;30(30):6119–6129.
   PubMed Web of Science ®Google Scholar
• Lam PL, Gambari R Advanced progress of microencapsulation technologies: in vivo and in vitro models for studying oral and transdermal drug deliveries. J Control Release 2014 2014 March 28;178: 25–45.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Salami H The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. J Microencapsul 2016 September;33(6):569–574.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Salami H Viability and topographical analysis of microencapsulated β-cells exposed to a biotransformed tertiary bile acid: an ex vivo study. Int J Nano Biomater 2016. 6 2 74
   Google Scholar
• Mooranian A, Negrulj R, Al-Salami H The effects of ionic gelation- vibrational jet flow technique in fabrication of microcapsules incorporating -cell: applications in diabetes. Curr Diabetes Rev 2017;13(1):91–96.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Salami H Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of beta-cells. Ther Deliv 2016;7(3):171–178.
   PubMed Web of Science ®Google Scholar
• Dorati R, Genta I, Modena T, et al. Microencapsulation of a hydrophilic model molecule through vibration nozzle and emulsion phase inversion technologies. J Microencapsul 2013;30(6):559–570.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Takechi R, et al. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv Transl Res 2018;8(3):543–551.
   PubMed Web of Science ®Google Scholar
• Mathavan S, Chen-Tan N, Arfuso F, et al. Morphological, stability, and hypoglycemic effects of new Gliclazide-bile acid microcapsules for Type 1 diabetes treatment: the microencapsulation of anti-diabetics using a microcapsule-stabilizing bile acid. Aaps Pharmscitech 2018 October;19(7):3009–3018.
   PubMed Web of Science ®Google Scholar
• Wagle SR, Walker D, Kovacevic B, et al.Micro-nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. Sci Rep 2020;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Raj Wagle S, Kovacevic B, et al. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Sci Rep 2020 2020 January 09;10(1):106.
   PubMed Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Chen-Tan N, et al.Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol 2016 August;44(5):1290–1297.
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Jamieson E, et al. Biological assessments of encapsulated pancreatic β-cells: their potential transplantation in diabetes. Cell Mol Bioeng 2016;9(4):530–537.
   Web of Science ®Google Scholar
• Heinzen C, Marison I, Berger A, et al. Use of vibration technology for jet break-up for encapsulation of cells, microbes and liquids in monodisperse microcapsules. Practical Aspects of Encapsulation Technologies. Dordrecht: Springer; 2002:19–25.
   Google Scholar
• Kim K, Yoon I, Chun I, et al. Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats. Drug Deliv 2011 January;18(1):79–83.
   PubMed Web of Science ®Google Scholar
• Stojančević M, Pavlović N, Goločorbin-Kon S, et al. Application of bile acids in drug formulation and delivery. Front Life Sci 2013;7(3–4):112–122.
   Web of Science ®Google Scholar
• Mooranian A, Tackechi R, Jamieson E, et al. Innovative microcapsules for pancreatic beta-cells harvested from mature double-transgenic Mice: cell imaging, viability, induced glucose-stimulated insulin measurements and proinflammatory cytokines analysis. Pharm Res 2017 June;34(6):1217–1223.
   PubMed Web of Science ®Google Scholar
• Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54(9):3618–3624.
   PubMed Web of Science ®Google Scholar
• Kecman S, Škrbić R, Badnjevic Cengic A, et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol Health Care 2019(Preprint):1–11.
   Google Scholar